Medtech
Evidence First: 5 Peer-Reviewed Medtech Startups Building Validation Early
DealBio tracks early-stage medtech startups across Europe and North America. These 5 are using peer-reviewed research to test core product assumptions before broad clinical adoption.
- Peer-Reviewed Research
- Clinical Evidence
- Medical Devices
- Validation
For an early medical-device startup, a publication is most useful when it answers a product question: can the sensor work on the body, can the device reach the tissue, can stimulation be timed reliably, or can a new material outperform the current standard?
The five startups below use published evidence at different points in development, but each has already tested a technical claim that matters directly to the product it is trying to commercialize.
At a Glance
- Clee MedicalSwitzerland2024Real-time neurosurgical imaging
- VRiTCanada2025Handheld wound bioprinting
- SkaaltecSwitzerland2026Movement-paired neurostimulation
- DXcreteNetherlands2025Sweat-based kidney monitoring
- M3NephronNetherlands2025Mixed-matrix dialysis membranes
Building real-time tissue imaging and AI guidance for minimally invasive brain surgery.
- Country
Switzerland- Founded
- 2024
- Sector
- Medtech
- Funding stage
- Seed or earlier
- Founders
Why Clee Medical stands out
Clee Medical has already moved its Neuro Access system into 11 neurosurgical procedures and published peer-reviewed in vivo, meaning in living tissue, results showing that the probe could distinguish tissue and detect blood flow.
The startup was spun out of Wyss Geneva and has raised a seed round led by High-Tech Gründerfonds, alongside CHF 270,000 from the W.A. de Vigier Award and Venture Kick.
What Clee Medical is building
Neuro Access is a single-use probe combining optical coherence tomography, a light-based method for cross-sectional tissue imaging, with software that classifies tissue and detects blood flow as the surgeon advances.
The goal is to add live information along narrow surgical trajectories, where pre-operative scans can become less reliable after the brain shifts during surgery.
02
VRiT
Developing a handheld bioprinter to deliver stem cells onto burn and trauma wounds.
- Country
Canada- Founded
- 2025
- Sector
- Medtech
- Funding stage
- Seed or earlier
- Founders
Why VRiT stands out
VRiT builds on a peer-reviewed tissue-printing program with intellectual-property protection. Co-founder Axel Guenther is senior author of the 2018 study describing the first device to form tissue directly on a wound and is named on two granted US patents covering the approach.
A large-animal burn study showed faster skin regrowth and new blood-vessel formation after printing stem-cell-containing material onto wounds, while a second peer-reviewed bioprinting paper followed in 2026.
What VRiT is building
VRiT is developing INSITE, a handheld bioprinter, a device that deposits biomaterial or cells directly onto tissue, for use on wounds during surgery. Its SHIELD product adds mesenchymal stem cells, cells that can support tissue repair, to the printed material.
The platform is designed to reduce dependence on autografts, skin transferred from another part of the same patient, particularly in severe burns where healthy donor skin can be limited.
03
Skaaltec
Developing a wearable nerve-stimulation system to improve arm recovery after stroke.
- Country
- Switzerland
- Founded
- 2026
- Sector
- Medtech
- Funding stage
- Seed or earlier
Why Skaaltec stands out
Skaaltec has peer-reviewed feasibility data for SmartVNS. In a JNER study, the system triggered stimulation on 50.4% of functional movements versus 23.4% with therapist triggering, while maintaining similar precision.
A separate 2026 Journal of Neuroscience study found that movement-paired ear stimulation selectively activated motor circuitry. The startup has also secured a CHF 150,000 InnoBooster grant and repeat Future of Health support.
What Skaaltec is building
SmartVNS pairs a wrist motion sensor with non-invasive stimulation of a vagus nerve branch, part of a major nerve linking the brain with the heart, lungs and digestive system, in the outer ear. When the sensor detects a functional arm movement, the system automatically triggers a short stimulation pulse.
The wearable is designed to pair stimulation with more rehabilitation movements without requiring a therapist to trigger every pulse, supporting use in both clinic and home settings.
04
DXcrete
Developing a sweat-sensing patch for frequent kidney-function monitoring.
- Country
Netherlands- Founded
- 2025
- Sector
- Medtech
- Funding stage
- Seed or earlier
- Founders
Why DXcrete stands out
DXcrete builds on peer-reviewed microfluidics, technology for handling tiny liquid volumes in small channels, from Eindhoven University of Technology. A 2024 Lab on a Chip study demonstrated on-body transport of approximately one-nanolitre sweat droplets at resting sweat rates, validating the core fluid-handling approach behind the wearable.
The startup has licensed sweat-sensing IP from Philips and secured €185,000 through NWO Faculty of Impact, while moving precision glass components toward pilot production.
What DXcrete is building
DXcrete is developing BEA, a skin-worn patch that collects sweat from individual glands and uses electrowetting, electrically controlled movement of tiny liquid droplets, to move them to an on-chip creatinine sensor.
The system is designed to work while the wearer is at rest, creating a route toward more frequent kidney-function measurements outside scheduled laboratory testing.
Developing dialysis filters that improve toxin removal and regenerate dialysate.
- Country
- Netherlands
- Founded
- 2025
- Sector
- Medtech
- Funding stage
- Seed or earlier
Why M3Nephron stands out
M3Nephron builds on University of Twente membrane research tested in human plasma. Its mixed-matrix membranes, filters that combine a membrane with adsorptive particles, removed two to three times more protein-bound toxins, waste molecules attached to blood proteins that conventional dialysis removes poorly, than conventional dialysis membranes.
The core technology is protected by a granted US patent, while Startupfonds Overijssel and imec.istart.nl have backed commercialization of the university spin-off.
What M3Nephron is building
M3Nephron is developing mixed-matrix membrane dialyzers that combine filtration and adsorption, binding selected molecules to a material, to remove toxins that conventional hemodialysis handles poorly.
The same membrane architecture is designed to regenerate dialysate, the fluid used during dialysis to remove waste from blood, for reuse, reducing water and fluid requirements and supporting more compact home and portable dialysis systems.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Peer-reviewed evidence strengthens the product case
Each startup has already generated peer-reviewed evidence around a central part of its product: live tissue imaging at Clee Medical, wound deposition and regeneration at VRiT, movement-triggered stimulation at Skaaltec, sweat handling at rest at DXcrete, and toxin removal in human plasma at M3Nephron.
Together, these studies give the startups more than academic credibility. The published work supports the core technology each team is building into a product, providing a stronger foundation for product development, clinical collaboration and commercialization. For investors, that makes the evidence especially useful because it is directly connected to the technology expected to create value.
Methodology
DealBio selected these startups from its coverage of early-stage health and longevity startups, focusing on medtech ventures with peer-reviewed evidence that directly supports a core technical or biological claim in the product. The selection spans surgical imaging, regenerative devices, neurostimulation, wearable sensing and dialysis technology.
DealBio builds its Startup Briefs using publicly available startup materials, ecosystem sources, market references and professional profiles.